Phencyclidine-induced deficits in prepulse inhibition of startle are blocked by prazosin, an alpha-1 noradrenergic antagonist

Journal of Pharmacology and Experimental Therapeutics

Volumn 283, Issue 2, 1997, Pages 666-674

  Bakshi, Vaishali P ^a   Geyer, Mark A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 METHOXY 1,4 BENZODIOXAN 2 YL) 2 IMIDAZOLINE; 4 AMINOBUTYRIC ACID RECEPTOR; ALPHA 1 ADRENERGIC RECEPTOR; ALPHA 2 ADRENERGIC RECEPTOR; APOMORPHINE; CLOZAPINE; MUSCARINIC M1 RECEPTOR; N METHYL DEXTRO ASPARTIC ACID; OLANZAPINE; PHENCYCLIDINE; PIRENZEPINE; PITRAZEPIN; PRAZOSIN; QUETIAPINE; RECEPTOR SUBTYPE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG ANTAGONISM; NEUROTRANSMISSION; NONHUMAN; PREPULSE INHIBITION; PRIORITY JOURNAL; RAT; SCHIZOPHRENIA; SENSORIMOTOR FUNCTION; STARTLE REFLEX;

ADRENERGIC ALPHA-ANTAGONISTS; ANIMALS; APOMORPHINE; MALE; MUSCARINIC ANTAGONISTS; PHENCYCLIDINE; PRAZOSIN; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, ADRENERGIC, ALPHA-1; RECEPTORS, ADRENERGIC, ALPHA-2; RECEPTORS, GABA-A; STARTLE REACTION;

EID: 0030832819     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (74)

1. ADLER, L. E., PANG, K., GERHARDT, G. AND ROSE, G. M.: Modulation of the gating of auditory evoked potentials by norepinephrine: Pharmacological evidence obtained using a selective neurotoxin. Biol. Psychiatry 24: 179-190, 1988.
2. ALLEN, R. M. AND YOUNG, S. J.: Phencyclidine-induced psychosis. Am. J. Psychiatry 135: 1081-1084, 1978.
3. BAKSHI, V. P. AND GEYER, M. A.: Antagonism of phencyclidine-induced deficits in prepulse inhibition by the putative atypical antipsychotic olanzapine. Psychopharmacology 122: 198-201, 1995.
4. BAKSHI, V. P. AND GEYER, M. A.: Neuroanatomical localization of dizocilpine-induced deficits in prepulse inhibition of the startle response. Soc. Neurosci. Abst. 22: 178, 1996.
5. BAKSHI, V. P., SWERDLOW, N. R. AND GEYER, M. A.: Clozapine antagonizes phencyclidine-induced deficits in sensorimotor gating of the startle response. J. Pharmacol. Exp. Ther. 271: 787-794, 1994.
6. BALDESSARINI, R. J., HUSTON-LYONS, D., CAMPBELL, A., MARSH E., AND COHEN, B. M.: Do central antiadrenergic actions contribute to the atypical properties of clozapine? Br. J. Psychiatry 160: suppl. 17, 12-16, 1992.
7. BALSTER, R. L.: The behavioral pharmacology of phencyclidine. In Psychopharmacology: The Third Generation of Progress, ed. by H. Y. Meltzer, pp. 1573-1579, Raven Press, New York, 1987.
8. BIRD, E. D., SPOKES, E. G. AND IVERSEN L. L.: Brain norepinephrine and dopamine in schizophrenia. Science (Wash, DC) 204: 93-94, 1979.
9. BOLINO, F., DI MICHELE, V., DI CICCO, L., MANNA, V., DANELUZZO, E. AND CASSACHIA, M.: Sensorimotor gating and habituation evoked by electrocutaneous stimulation in schizophrenia. Biol. Psychiatry 36: 670-679, 1994.
10. BOWYER, J. F., SPUHLER, K. P. AND WEINER, N.: Effects of phencyclidine, amphetamine and related compounds on dopamine release from and uptake into striatal synaptosomes. J. Pharmacol. Exp. Ther. 229: 671-680, 1984.
11. BRAFF, D. L. AND GEYER, M. A.: Sensorimotor gating and schizophrenia: Human and animal model studies. Arch. Gen. Psychiatry 47: 181-188, 1990.
12. BRAFF, D. L., GRILLON, C. AND GEYER, M. A.: Gating and habituation of the startle reflex in schizophrenic patients. Arch. Gen. Psychiatry 49: 206-215, 1992.
13. BRAFF, D. L., STONE, C., CALLAWAY, E., GEYER, M. A., GLICK, I. D. AND BALI, L.: Prestimulus effects on human startle reflex in normals and schizophrenics. Psychophysiology 15: 339-343, 1978.
14. BREIER, A.: Clozapine and noradrenergic function: Support for a novel hypothesis for superior efficacy. J. Clin. Psychiat. 55: suppl. B, 122-125, 1994.
15. BREIER, A., WOLKOWITZ, O. M., ROY, A., POTTER, W. Z. AND PICKAR, D.: Plasma norepinephrine in chronic schizophrenia. Am. J. Psychiatry 147: 1467-1470, 1990.
16. BYMASTER, F. P., CALLIGARO, D. O., FALCONE, J. F., MARSH, R. D., MOORE, N. A., TYE, N. C., SEEMAN, P. AND WONG, D. T.: Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 14: 87-96, 1996.
17. BYMASTER, F. P., HEATH, I., HENDRIX, J. C. AND SHANNON, H. E.: Comparative behavioral and neurochemical activities of cholinergic antagonists in rats. J. Pharmacol. Exp. Ther. 267: 16-24, 1993.
18. CADENHEAD, K. S., GEYER, M. A. AND BRAFF, D. L.: Impaired startle prepulse inhibition and habituation in patients with schizotypal personality disorder. Am. J. Psychiatry 150: 1862-1867, 1993.
19. COHEN, B. M. AND LIPINSKI, J. F.: In vivo potencies of antipsychotic drugs in blocking alpha 1 noradrenergic and dopamine D2 receptors: Implications for drug mechanisms of action. Life Sci. 39: 2571-2580, 1986.
20. COWARD, D. M.: General pharmacology of clozapine. Br. J. Psychiatry 160: suppl 17, 5-11, 1992.
21. COWARD, D. M., IMPERATO, A., URWYLER, S. AND WHITE, T. G.: Biochemical and behavioral properties of clozapine. Psychopharmacology 99: S6-S12, 1989.
22. DAVIS, M., KEHNE, J. H. AND COMMISSARIS, R. L.: Antagonism of apomorphine-enhanced startle by alpha 1-adrenergic antagonists. Eur. J. Pharmacol. 108: 233-241, 1985.
23. FARLEY, I. J., PRICE, K. S., MCCULLOUGH, E., DECK, J. H. N., HORDYNSKI, W. AND HORNYKIEWICZ, O.: Norepinephrine in chronic paranoid schizophrenia: Above-normal levels in limbic forebrain. Science 200: 456-458, 1978.
24. FRENCH, E. D.: Phencyclidine and the midbrain dopamine system: Electrophysiology and behavior. Neurotoxicol. Teratol. 16: 355-362, 1994.
25. FRENCH, E. D. AND VANTINI, G.: Phencyclidine-induced locomotor activity in the rat is blocked by 6-hydroxydopamine lesion of the nucleus accumbens: Comparisons to other psychomotor stimulants. Psychopharmacology 82: 83-88, 1984.
26. A antagonist. Neurosci. Lett. 45: 311-316, 1984.
27. GEYER, M. A., SWERDLOW, N. R., MANSBACH, R. S. AND BRAFF, D. L.: Startle response models of sensorimotor gating and habituation deficits in schizophrenia. Brain Res. Bull. 25: 485-498, 1990.
28. GRILLON, C., AMELI, R., CHARNEY, D. S., KRYSTAL, J. AND BRAFF, D. L.: Startle gating deficits occur across prepulse intensities in schizophrenic patients. Biol. Psychiatry 32: 939-943, 1992.
29. HOFFMAN, D. C.: Typical and atypical neuroleptics antagonize MK-801-induced locomotion and stereotypy in rats. J. Neural Transm. 89: 1-10, 1992.
30. HOFFMAN, D. C., DONOVAN, H. AND CASSELLA, J. V.: The effects of haloperidol and clozapine on the disruption of sensorimotor gating induced by the noncompetitive glutamate antagonist MK-801. Psychopharmacology 111: 339-344, 1993.
31. HOFFMAN, H. S. AND ISON, J. R.: Reflex modification in the domain of startle. I. Some empirical findings and their implications for how the nervous system processes sensory input. Psychol. Rev. 87: 175-189, 1980.
32. HOMMER, D. W., ZAHN, T. P., PICKAR, D. AND VAN KAMMEN, D. P.: Prazosin, a specific alpha1-noradrenergic receptor antagonist, has no effect on symptoms but increases autonomic arousal in schizophrenic patients. Psychiatry Res. 11: 193-204, 1984.
33. HONDO, H., YONEZAWA, Y., NAKAHARA, T., NAKAMURA, K., HIRANO, M., UCHIMURA, H. AND TASHIRO, N.: Effect of phencyclidine on dopamine release in the rat prefrontal cortex; an in vivo microdialysis study. Brain Res. 633: 337-342, 1994.
34. HORI, T., SUZUKI, T., BABA, A., ABE, S., YAMAMOTO, T., MOROJI, T. AND SHIRAISHI, H.: Effects of phencyclidine metabolites on serotonin uptake in rat brain. Neurosci. Lett. 209: 153-156, 1996.
35. HORNUNG, R., PRESEK, P. AND GLOSSMANN, H.: Alpha adrenoceptors in rat brain: Direct identification with prazosin. Naunyn-Schmiedeberg's Arch. Pharmacol. 308: 223-230, 1979.
36. HORNYKIEWICZ, O.: Brain catecholamines in schizophrenia - a good case for noradrenaline. Nature (Lond.) 299: 484-486, 1982.
37. HUTSON, P. H. AND HOGG, J. E.: Effects of and interactions between antagonists for different sites on the NMDA receptor complex on hippocampal and striatal acetylcholine efflux in vivo. Eur. J. Pharmacol. 295: 45-52, 1996.
38. ISON, J. R. AND HOFFMAN, H. S.: Reflex modification in the domain of startle. II. The anomalous history of a robust and ubiquitous phenomenon. Psychol. Bull. 94: 3-17, 1983.
39. JAVITT, D. C.: Negative schizophrenic symptomatology and the PCP (phencyclidine) model of schizophrenia. Hillside J. Clin. Psychiatry 9: 12-35, 1987.
40. JOHANSSON, C., JACKSON, D. M. AND SVENSSON, L.: The atypical antipsychotic, remoxipride, blocks phencyclidine-induced disruption of prepulse inhibition in the rat. Psychopharmacology 116: 437-442, 1994a.
41. JOHANSSON, C., JACKSON, D. M., ZHANG, J. AND SVENSSON, L.: Prepulse inhibition of acoustic startle, a measure of sensorimotor gating: Effects of antipsychotics and other agents in rats. Pharmacol. Biochem. Behav. 52: 649-654, 1994b.
42. JOHNSON, K. M. AND HILLMAN, G. R.: Comparisons between phencyclidine, its monohydroxylated metabolites, and the stereoisomers of N-allyl-N-normetazocine (SKF 10047) as inhibitors of the muscarinic receptor and acetylcholinesterase. J. Pharm. Pharmacol. 34: 462-464, 1982.
43. KANE, J., HONIGFELD, G., SINGER, J. AND MELTZER, H.: Clozapine for the treatment-resistant schizophrenic. Arch. Gen. Psychiatry 45: 789-796, 1988.
44. KARPER, L. P., GRILLON, C., MORISSEY, K., ABI-SAAB, D., MORGAN, C. A., CHARNEY, D. S. AND KRYSTAL, J. H.: The effect of ketamine on the acoustic startle response. Soc. Neurosci. Abst. 20: 482, 1994.
45. KEITH, V. A., MANSBACH, R. S. AND GEYER, M. A.: Failure of haloperidol to block the effects of phencyclidine and dizocilpine on prepulse inhibition of startle. Biol. Psychiatry 30: 557-566, 1991.
46. KEMALI, D., MAJ, M., GALDERISI, S., GRAZIA, M. AND STARACE, F.: Factors associated with increased noradrenaline levels in schizophrenic patients. Prog. Neuro-Psychopharmacol. Biol. Psychiat. 14: 49-59, 1990.
47. KLEINMAN, J. E., BRIDGE, P., KAROUM, F., SPECIALE, S., STAUB, R., ZALCMAN, S., GILLIN, J. C. AND WYATT, R. C.: Catecholamines and metabolites in the brains of psychotics and normals: Post-mortem studies. In Catecholamines: Basic and Clinical Frontiers, ed. by E. Usdin, I. J. Kopin and J. Barchas, pp. 1845-1847, Pergamon Press, New York, NY, 1979.
48. KRYSTAL, J. H., KARPER, L. P., SEIBYL, J. P., FREEMAN, G. K., DELANEY, R., BREMNER J. D., HENINGER, G. R., BOWERS, M. B. AND CHARNEY, D. S.: Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Arch. Gen. Psychiatry 51: 199-214, 1994.
49. 2a-adrenoceptors. Eur. J. Pharmacol. 167: 95-104, 1989.
50. 2 receptors. Psychopharmacology 112: S40-S54, 1993.
51. LILLRANK, S. M., O'CONNOR, W. T., OJA, S. S. AND UNGERSTEDT, U.: Systemic phencyclidine administration is associated with increased dopamine, GABA, and 5-HIAA levels in the dorsal striatum of conscious rats: An in vivo microdialysis study. J. Neural Transm. 95: 145-155, 1994.
52. LUISADA, P. V.: The phencyclidine psychosis: Phenomenology and treatment. In Phencyclidine (PCP) Abuse: An Appraisal, NIDA Monograph Series 21, ed. by R. C. Petersen and R. C. Stillman, pp. 241-253, US Government Printing Office, Washington, DC, 1978.
53. 3H]quinuclidinylbenzilate binding to muscarinic cholinergic receptors in rat brain. J. Pharmacol. Exp. Ther. 228: 648-655, 1984.
54. MANSBACH, R. S. AND GEYER, M. A.: Effects of phencyclidine and phencyclidine biologs on sensorimotor gating in the rat. Neuropsychopharmacology 2: 299-308, 1989.
55. MANSBACH, R. S. AND GEYER, M. A.: Parametric determinants in pre-stimulus modification of acoustic startle: Interaction with ketamine. Psychopharmacology 105: 162-168, 1991.
56. MANSBACH, R. S., GEYER, M. A. AND BRAFF, D. L.: Dopaminergic stimulation disrupts sensorimotor gating in the rat. Psychopharmacology 94: 507-514, 1988.
57. MATHE, J. M., NOMIKOS, G. G., HILDEBRAND, B. E., HERTEL, P. AND SVENSSON, T. H.: Prazosin inhibits MK-801-induced hyperlocomotion and dopamine release in the nucleus accumbens. Eur. J. Pharmacol. 309: 1-11, 1996.
58. MILLER, C. L., BICKFORD, P. C., LUNTZ-LEYBMAN, V., ADLER, L. E., GERHARDT, G. A. AND FREEDMAN, R.: Phencyclidine and auditory sensory gating in the hippocampus of the rat. Neuropharmacology 31: 1041-1048, 1992.
59. MOORE, N. A., CALLICARO, D. O., WONG, D. T., BYMASTER, F. AND TYE, N. C.: The pharmacology of olanzapine and other new antipsychotic agents. Curr. Op. Investig. Drugs 2: 281-293, 1993.
60. MOORE, N. A., TUPPER, D. E. AND HOTTEN, T. M.: Olanzapine. Drugs of the Future 19: 114-117, 1994.
61. PRINSSEN, E. P. M., ELLENBROEK, B. A. AND COOLS, A. R.: Combined antagonism of adrenoceptors and dopamine and 5-HT receptors underlies the atypical profile of clozapine. Eur. J. Pharmacol. 262: 167-170, 1994.
62. ROGERS, C. AND LEMAIRE, S.: Role of the sigma receptor in the inhibition of [3H]-noradrenaline uptake in brain synaptosomes and adrenal chromaffin cells. Br. J. Pharmacol. 103: 1917-1922, 1991.
63. SALLER, C. F. AND SALAMA, A. I.: Seroquel: Biochemical profile of a potential atypical antipsychotic. Psychopharmacology 112: 285-292, 1993.
64. SIVIY, S. M., FLEISCHHAUER, A. E., KUHLMAN, S. J. AND ATRENS, D. M.: Effects of alpha-2 adrenoceptor antagonists on rough-and-tumble play in juvenile rats: Evidence for a site of action independent of non-adrenoceptor imidazoline binding sites. Psychopharmacology 113: 493-499, 1994.
65. SMITH, R. C., MELTZER, H. Y., ARORA, R. C. AND DAVIS, J. M.: Effects of phencyclidine on [3H]catecholamine and [3H]serotonin uptake in synaptosomal preparations from rat brain. Biochem. Pharmacol. 26: 1435-1439, 1977.
66. SNYDER, S. H.: Psychotogenic drugs as models for schizophrenia. Comments on "The current status of the dopamine hypothesis of schizophrenia." Neuropsychopharmacology 1: 197-199, 1988.
67. SQUIRES, R. F. AND SAEDRUP, E.: Mono N-aryl ethylenediamine and piperazine derivatives are GABAA receptor blockers: Implications for psychiatry. Neurochem. Res. 18: 787-793, 1993.
68. STEVENS, K. E., FULLER, L. L. AND ROSE, G. M.: Dopaminergic and noradrenergic modulation of amphetamine-induced changes in auditory gating. Brain Res. 555: 91-98, 1991.
69. SVENSSON, T. H., MATHE, J. M., ANDERSSON, J. L., NOMIKOS, G. G., HILDEBRAND, B. E. AND MARCUS, M.: Mode of action of atypical neuroleptics in relation to the phencyclidine model of schizophrenia: Role of 5-HT2 receptor and α1-adrenoceptor antagonism. J. Clin. Psychopharmacology 15: suppl. 1, 11S-18S, 1995.
70. SWERDLOW, N. R., BAKSHI, V. P. AND GEYER, M. A.: Seroquel restores sensorimotor gating in phencyclidine-treated rats. J. Pharmacol. Exp. Ther. 279: 1290-1299, 1996.
71. SWERDLOW, N. R., KEITH, V. A., BRAFF, D. L. AND GEYER, M. A.: Effects of spiperone, raclopride, SCH23390 and clozapine on apomorphine-inhibition of sensorimotor gating of the startle response in the rat. J. Pharmacol. Exp. Ther. 256: 530-536, 1991.
72. VAN KAMMEN, D. P., PETERS, J., VAN KAMMEN, W. B., NUGENT, A., GOETZ, K. L., YAO, J. AND LINNOILA, M.: CSF norepinephrine in schizophrenia is elevated prior to relapse after haloperidol withdrawal. Biol. Psychiatry 26: 176-188, 1989.
73. VARTY, G. B. AND HIGGINS, G. A.: Differences between three rat strains in sensitivity to prepulse inhibition of an acoustic startle response: Influence of apomorphine and phencyclidine pretreatment. J. Psychopharmacology 8: 148-156, 1994.
74. WILEY, J. L.: Clozapine's effects on phencyclidine-induced disruption of Prepulse inhibition of the acoustic startle response. Pharmacol. Biochem. Behav. 49: 1025-1028, 1994.